The newest reporting from every desk, ordered by publication time. New stories appear here immediately after publication.
Researchers linked an age-associated gut bacterium to healthier biomarker profiles in Chinese cohorts, then reported functional and inflammatory improvements after treating aged mice. The work identifies a testable microbiome pathway but provides no evidence that the bacterium or its metabolite slows aging in people.
A new life-course analysis concludes that diseases concentrated in later life now impose the largest expected lifetime burden in every income group. Its projections strengthen the case for healthspan-focused prevention, but they model hypothetical reductions in disease prevalence rather than tested interventions.
Mimrylo reduced phlebotomy eligibility when added to existing care in a 293-person phase 3 trial. The approval establishes a new way to control excess red-cell production, although effects on thrombosis and survival remain unanswered.
A post hoc analysis found that a physical-activity and nutrition program prolonged time free from mobility disability or death among frail older adults with multiple chronic conditions. Apparent differences between disease clusters remain exploratory because the formal interaction test was not significant.
An analysis of more than 50,000 companion dogs found that accumulating chronic conditions was associated with progressively higher mortality. The observational findings support multimorbidity as a comparative-aging endpoint but do not establish how treating disease combinations would affect survival.
Researchers temporarily disabled proteins with a masked synthetic amino acid, then restored their activity in nitric-oxide-rich environments. The platform worked across several protein classes and mouse models, but remains far from clinical use.
In the 360-person ACASA-TAVI trial, anticoagulant monotherapy produced less subclinical leaflet thrombosis than aspirin after transcatheter aortic valve implantation. The study was not large or long enough to establish better survival or longer-lasting replacement valves.
Experiments in mice identified an inflammatory signal that spreads from aging egg cells to their supporting cells. Genetic and drug interventions improved ovarian endpoints in the animals, but the approach has not been tested as a treatment in humans.
AZD5462 reduced vascular resistance in one heart-failure cohort, while its ventricular-remodeling result in another narrowly missed conventional statistical significance. The study establishes activity at a peptide-hormone pathway but does not show fewer hospitalizations or deaths.
In a small controlled-feeding trial, three diets produced comparable weight loss and improved muscle insulin sensitivity, but the ketogenic group had larger reductions in liver fat and glucose-related measures. The short intervention did not test long-term adherence, cardiovascular events or progression of liver disease.
Genetic and dietary experiments connect a low-protein diet to healthier fat-cell metabolism through FGF21 signaling. The findings clarify a longevity-related mechanism but do not establish that protein restriction slows human aging.
The agency says at least 30 patients experienced adverse events after receiving compounded intravenous glutathione made with material labeled for dietary-supplement use. Two Texas pharmacies have recalled products after testing identified elevated bacterial endotoxin levels.